Diana Zuckerman is president of the National Center for Health Research, a nonprofit think tank based in Washington, D.C.
Diana Zuckerman
President
National Center for Health Research
From this contributor
How the new U.S. ‘Right to Try’ law could harm people with autism
People with autism already have access to experimental treatments; the new law could make that access more dangerous.
How the new U.S. ‘Right to Try’ law could harm people with autism
By
Diana Zuckerman
3 July 2018 | 5 min read
Why the 21st Century Cures Act could be disastrous for medicine
A new bill threatens to lower the scientific standards that have made the Food and Drug Administration's approval the gold standard worldwide.
Why the 21st Century Cures Act could be disastrous for medicine
By
Diana Zuckerman
1 December 2016 | 6 min read
Explore more from The Transmitter
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
By
Chand Chandrasekaran
20 April 2026 | 6 min read
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
By
Angie Voyles Askham
17 April 2026 | 8 min read
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
By
Charles Q. Choi
16 April 2026 | 4 min read